FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1781646350> ?p ?o ?g. }

• W1781646350 endingPage "93" @default.
• W1781646350 startingPage "5385" @default.
• W1781646350 abstract "Incidence of oropharyngeal head and neck squamous cell carcinoma (HNSCC) induced by the human papilloma virus (HPV) is rising. HNSCC is the sixth most common neoplasia worldwide. The survival rate remains poor, thus innovative therapy approaches are necessary. Everolimus, an inhibitor of the mammalian target of rapamycin, as well as the multi-tyrosine kinase inhibitors sorafenib (targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor and RAF) and sunitinib (targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, stem cell factor receptor, RET proto-oncogene and colony-stimulating factor), have shown a remarkable antitumor effect against various tumor entities, with moderate side-effects. These drugs are administered orally, which should lead to higher patient compliance and less hospitalisation.This study sought to evaluate the expression of PDGFR α/β and hypoxia-inducible factor-1α (HIF-1α) and their alterations induced by everolimus, sorafenib and sunitinib in chemonaïve HPV-positive and HPV-negative HNSCC. To our knowledge, this is the first in vitro study to investigate such cases.We incubated HPV-positive CERV196 and HPV-negative HNSCC 11A and 14C cells for 2 to 8 days with increasing concentration of drugs. Expression of PDGFR α/β and HIF-1α was measured by enzyme-linked immunosorbent assay and compared to a chemonaïve controls.Our study showed that PDGFR α/β and HIF-1α were expressed in all three cell lines. Incubation with everolimus, sorafenib or sunitinib led to a decrease in PDGFR α/β and HIF-1α expression, depending on the HPV status. A statistically significant alteration of PDGFR α/β was detected in CERV196 only. Thus, HPV-positive HNSCC exhibited a higher sensitivity to the drugs used compared to HPV-negative HNSCC 11A and 14C tumor cells. A significant reduction of HIF-1α was measured for HNSCC 11A and 14C only. An escalation of drug concentration had no significant effect.We showed that these novel agents led to a significant reduction of PDGFR and HIF-1α, depending on the HPV status. HPV positivity is associated with increased chemosensitivity and may be associated with better locoregional control and overall patient survival compared to HPV negativity. Further studies are necessary to investigate the efficacy and safety of these agents in the treatment of HPV-positive and -negative HNSCC in vivo." @default.
• W1781646350 created "2016-06-24" @default.
• W1781646350 creator A5000383635 @default.
• W1781646350 creator A5002719310 @default.
• W1781646350 creator A5017084325 @default.
• W1781646350 creator A5024074912 @default.
• W1781646350 creator A5045121029 @default.
• W1781646350 creator A5063921909 @default.
• W1781646350 creator A5065438303 @default.
• W1781646350 creator A5066825043 @default.
• W1781646350 creator A5069555057 @default.
• W1781646350 creator A5084526782 @default.
• W1781646350 date "2013-12-01" @default.
• W1781646350 modified "2023-10-14" @default.
• W1781646350 title "Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro." @default.
• W1781646350 cites W111637981 @default.
• W1781646350 cites W1482866244 @default.
• W1781646350 cites W1491779959 @default.
• W1781646350 cites W1969398614 @default.
• W1781646350 cites W1969426527 @default.
• W1781646350 cites W1970737635 @default.
• W1781646350 cites W1976206793 @default.
• W1781646350 cites W1978580856 @default.
• W1781646350 cites W1979771543 @default.
• W1781646350 cites W1981989535 @default.
• W1781646350 cites W1982030800 @default.
• W1781646350 cites W1983820109 @default.
• W1781646350 cites W1991827918 @default.
• W1781646350 cites W1991949008 @default.
• W1781646350 cites W1998349950 @default.
• W1781646350 cites W1999587521 @default.
• W1781646350 cites W2002784910 @default.
• W1781646350 cites W2008006907 @default.
• W1781646350 cites W2008714016 @default.
• W1781646350 cites W2012307085 @default.
• W1781646350 cites W2014087704 @default.
• W1781646350 cites W2014356708 @default.
• W1781646350 cites W2017626769 @default.
• W1781646350 cites W2018985358 @default.
• W1781646350 cites W2025033391 @default.
• W1781646350 cites W2026228130 @default.
• W1781646350 cites W2030575063 @default.
• W1781646350 cites W2031284585 @default.
• W1781646350 cites W2031984172 @default.
• W1781646350 cites W2034772593 @default.
• W1781646350 cites W2035757227 @default.
• W1781646350 cites W2037397309 @default.
• W1781646350 cites W2039422888 @default.
• W1781646350 cites W2039585951 @default.
• W1781646350 cites W2044828823 @default.
• W1781646350 cites W2045729789 @default.
• W1781646350 cites W2048258133 @default.
• W1781646350 cites W2051854622 @default.
• W1781646350 cites W2053373795 @default.
• W1781646350 cites W2062312459 @default.
• W1781646350 cites W2076959989 @default.
• W1781646350 cites W2080127092 @default.
• W1781646350 cites W2092620035 @default.
• W1781646350 cites W2095909276 @default.
• W1781646350 cites W2100623243 @default.
• W1781646350 cites W2100917720 @default.
• W1781646350 cites W2105653042 @default.
• W1781646350 cites W2110675408 @default.
• W1781646350 cites W2113672655 @default.
• W1781646350 cites W2124156250 @default.
• W1781646350 cites W2127605299 @default.
• W1781646350 cites W2130913838 @default.
• W1781646350 cites W2132239791 @default.
• W1781646350 cites W2132742086 @default.
• W1781646350 cites W2133183695 @default.
• W1781646350 cites W2136693809 @default.
• W1781646350 cites W2137063143 @default.
• W1781646350 cites W2138736317 @default.
• W1781646350 cites W2140407529 @default.
• W1781646350 cites W2143502075 @default.
• W1781646350 cites W2150800398 @default.
• W1781646350 cites W2163918907 @default.
• W1781646350 cites W2166350015 @default.
• W1781646350 cites W2169500587 @default.
• W1781646350 cites W2334648137 @default.
• W1781646350 cites W2367263653 @default.
• W1781646350 cites W2405567101 @default.
• W1781646350 cites W2747612914 @default.
• W1781646350 cites W2886259079 @default.
• W1781646350 cites W96337941 @default.
• W1781646350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24324073" @default.
• W1781646350 hasPublicationYear "2013" @default.
• W1781646350 type Work @default.
• W1781646350 sameAs 1781646350 @default.
• W1781646350 citedByCount "5" @default.
• W1781646350 countsByYear W17816463502015 @default.
• W1781646350 countsByYear W17816463502016 @default.
• W1781646350 countsByYear W17816463502018 @default.
• W1781646350 crossrefType "journal-article" @default.
• W1781646350 hasAuthorship W1781646350A5000383635 @default.
• W1781646350 hasAuthorship W1781646350A5002719310 @default.
• W1781646350 hasAuthorship W1781646350A5017084325 @default.
• W1781646350 hasAuthorship W1781646350A5024074912 @default.

• next